A Phase 3 interventional study of Apremilast (CC-10004) and Placebo in Psoriasis, sponsored by Amgen. Completed at 99 sites in 10 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-12-16.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.
Among the 44 studies testing apremilast in Psoriasis, this one is the 14th largest by enrollment, is one of 6 that started in 2018, is one of 18 in phase 3, and was the 25th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:
Syeda Sana Zaman · Sites in Pakistan
Ages 18–60 · Healthy volunteers
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
Amgen
Ages 18–60 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Zarmeen Khawar · Sites in Pakistan
Ages 18–65
By country, each count listing its studies:
apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 245 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 103 across the 44 interventional studies. Of the 34 that completed or were terminated, 26 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
61 studies in Psoriasis by Amgen: 1 open now, 1 under way, none of them phase 3. Of 60 finished, 35 (58%) have results posted.
Among the 61 studies in Psoriasis by Amgen, this one is the 27th largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2018, is one of 32 in phase 3, and was the 45th registered.
Amgen’s Psoriasis studies by the year they started, since 2000.
1 of the studies testing apremilast in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07908641AmgenComparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation | 2027-01-10 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing apremilast in Psoriasis, from their registry updates:
Among Amgen’s 61 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis.
At least 230 pediatric subjects (ages 6 through 17 years) will be randomized 2:1 to receive either apremilast or placebo for the first 16 weeks and then all subjects will receive apremilast during the 36 week Extension Phase for a total of 52 weeks. Randomization to apremilast arm or placebo arm will be stratified by age group (6 to 11 years or 12 to 17 years). Subjects will receive apremilast treatment of either 20 mg twice daily (BID) or 30 mg BID, depending on weight. This Phase 3 study is being conducted to evaluate the safety and efficacy of apremilast in the treatment of pediatric subjects.
Treatment will be assigned by weight with subjects 20 kg to \< 50 kg receiving apremilast 20 mg BID or placebo BID and subjects ≥ 50 kg receiving apremilast 30 mg BID or placebo BID. Total study duration is up to 71 weeks. Subjects completing all 52 weeks of the treatment and extension phase will be able to enter the Long-term study. Subjects not entering the Long-term study will return for 3 observational follow-up visits, 4, 8 and 14 weeks after last dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has moderate to severe plaque psoriasis at Screening and Baseline as defined by:
Exclusion Criteria:
Current or planned concurrent use of the following therapies that may have a possible effect on psoriasis
a. Topical therapy within 2 weeks prior to randomization (including but not limited to topical , topical retinoid or vitamin D analog preparations, tacrolimus, pimecrolimus, or anthralin/dithranol)
Exceptions*:
i. Low potency or weak corticosteroids (please refer to the Investigators' Manual) will be allowed as background therapy for treatment of the face, axillae and groin in accordance with manufacturer's suggested usage ii. Unmedicated skin moisturizer (eg, Eucerin®) will also be permitted for body lesions
*Subjects should not use these topical treatments within 24 hours prior to the clinic visit.
b. Conventional systemic therapy for psoriasis within 4 weeks prior to randomization c. Phototherapy treatment (ie, ultraviolet B [UVB], PUVA) within 4 weeks prior to randomization d. Biologic therapy within 4 weeks prior to randomization or 5 PK/PD half-lives (whichever is longer).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apremilast 20mg Twice Daily (BID)
Drug: Apremilast (CC-10004)
Apremilast 30mg Twice Daily (BID)
Drug: Apremilast (CC-10004)
Placebo tablet Twice Daily (BID)
Other: Placebo
Apremilast (CC-10004)
Placebo
Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16
The sPGA is the assessment by the Investigator of the overall disease severity of plaque psoriasis at the time of evaluation. The sPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation. The results presented are for the percentage of participants with a sPGA response. An sPGA response was defined as a score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline at Week 16.
Time frame: Baseline to Week 16
Percentage of Participants Who Achieved At Least 75% Reduction in Psoriasis Area Severity Index (PASI-75) From Baseline at Week 16
The Psoriasis Area Severity Index (PASI) is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. The results presented are for the percentage of participants with PASI-75. PASI-75 was defined as at least a 75% reduction in PASI score from baseline.
Time frame: Baseline and Week 16
Percentage of Participants Who Achieved At Least 50% Reduction in Psoriasis Area Severity Index (PASI-50) From Baseline at Week 16
The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. The results presented are for the percentage of participants with PASI-50. PASI-50 was defined as at least a 50% reduction in PASI score from baseline.
Time frame: Baseline and Week 16
Percentage Change From Baseline in Total PASI Score at Week 16
The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Positive percentage change from baseline scores indicate a worsening of disease severity, and negative percentage change from baseline scores indicate an improvement in disease severity.
Time frame: Baseline and Week 16
Percentage Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis at Week 16
BSA is a measurement of involved skin of the whole body affected by psoriasis, which ranges from 0% to 100%. Positive percentage change from baseline indicates that a greater BSA was affected by psoriasis. A negative percentage change from baseline indicates that a lesser BSA was affected by psoriasis.
Time frame: Baseline and Week 16
Percentage of Participants Who Achieved a Children's Dermatology Life Quality Index (CDLQI) Score of 0 or 1 at Week 16
The CDLQI is designed to measure the impact of skin disease on children's quality of life. The CDLQI measures how much the participant's psoriasis has affected them over the last week, and includes 10 questions with possible answers ranging from not at all (score of 0) to very much (score of 3). The CDLQI total score ranged from 0 (no effect on the participant's life) to 30 (extremely large effect on the participant's life). The results presented are for the percentage of participants who achieved a total CDLQI score of 0 or 1 at Week 16.
Time frame: Week 16
Change From Baseline in CDLQI Score at Week 16
The CDLQI is designed to measure the impact of skin disease on children's quality of life. The CDLQI measures how much the participant's psoriasis has affected them over the last week, and includes 10 questions with possible answers ranging from not at all (score of 0) to very much (score of 3). The CDLQI total score ranged from 0 (no effect on the participant's life) to 30 (extremely large effect on the participant's life). A positive change from baseline score indicates that a participant's quality of life has worsened. A negative change from baseline score indicates that a participant's quality of life has improved.
Time frame: Baseline and Week 16
Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) During the Placebo-controlled Phase
An adverse event (AE) was defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of the study. A TEAE is any AE that occurred after first dose of the investigational product.
Time frame: 16 weeks
Number of Participants Who Experienced a TEAE During the Apremilast Exposure Period
An AE was defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of the study. A TEAE is any AE that occurred after first dose of the investigational product.
Time frame: 52 weeks
Number of Participants Who Experienced a Treatment-emergent Serious Adverse Event (TESAE) During the Placebo-controlled Phase
A TESAE is any AE occurring at any dose after first dose that results in death, is life-threatening (ie, in the opinion of the Investigator, the participant is at immediate risk of death from the AE), requires inpatient hospitalization or prolongation of existing hospitalization (hospitalization is defined as an inpatient admission, regardless of length of stay), results in persistent or significant disability/incapacity (a substantial disruption of the participant's ability to conduct normal life functions), is a congenital anomaly/birth defect, or constitutes an important medical event.
Time frame: 16 weeks
Number of Participants Who Experienced a TESAE During the Apremilast Exposure Period
A TESAE is any AE occurring at any dose after first dose that results in death, is life-threatening (ie, in the opinion of the Investigator, the participant is at immediate risk of death from the AE), requires inpatient hospitalization or prolongation of existing hospitalization (hospitalization is defined as an inpatient admission, regardless of length of stay), results in persistent or significant disability/incapacity (a substantial disruption of the participant's ability to conduct normal life functions), is a congenital anomaly/birth defect, or constitutes an important medical event.
Time frame: 52 weeks
Number of Participants Who Experienced a Treatment-related Adverse Event (TRAE) During the Placebo-controlled Phase
A TREAE is any AE that is determined by the Investigator to have a possibly causal relationship to the investigational product.
Time frame: 16 weeks
Number of Participants Who Experienced a TRAE During the Apremilast Exposure Period
A TREAE is any AE that is determined by the Investigator to have a possibly causal relationship to the investigational product.
Time frame: 52 weeks
Number of Participants With Diarrhea During the Placebo-controlled Phase
Diarrhea was defined as having 3 or more liquid or watery stools in a day. Participants and their parent/guardian were supplied with diaries (either paper or electronic) that were filled out daily to record and describe any diarrhea and associated symptoms.
Time frame: Up to approximately 113 days
Number of Participants With Diarrhea During the Apremilast Exposure Period
Diarrhea was defined as having 3 or more liquid or watery stools in a day. Participants and their parent/guardian were supplied with diaries (either paper or electronic) that were filled out daily to record and describe any diarrhea and associated symptoms.
Time frame: Day 1 up to approximately 365 days
Number of Participants With Diarrhea Symptoms During the Placebo-controlled Phase
Diarrhea symptoms were nausea, vomiting, abdominal cramps, abdominal pain, fever, bloating, and other symptoms. Participants and their parent/guardian were supplied with diaries (either paper or electronic) that were filled out daily to record and describe any diarrhea and associated symptoms.
Time frame: Up to approximately 113 days
Number of Participants With Diarrhea Symptoms During the Apremilast Exposure Period
Diarrhea symptoms were nausea, vomiting, abdominal cramps, abdominal pain, fever, bloating, and other symptoms. Participants and their parent/guardian were supplied with diaries (either paper or electronic) that were filled out daily to record and describe any diarrhea and associated symptoms.
Time frame: Day 1 up to approximately 365 days
Number of Participants With Suicidal Ideation or Behavior Per the Columbia-Suicide Severity Rating Scale (C-SSRS) During the Placebo-controlled Phase
The C-SSRS is a questionnaire that is used to assess suicidal ideation and behavior. The C-SSRS questionnaire measures suicidal ideation, intensity of ideation, and suicidal behaviors. Results presented are for the number of participants who recorded suicidal ideation or behavior on the C-SSRS.
Time frame: 16 weeks
Number of Participants With Suicidal Ideation or Behavior Per the C-SSRS During the Apremilast-extension Phase
The C-SSRS is a questionnaire that is used to assess suicidal ideation and behavior. The C-SSRS questionnaire measures suicidal ideation, intensity of ideation, and suicidal behaviors. Results presented are for the number of participants who recorded suicidal ideation or behavior on the C-SSRS.
Time frame: Week 16 to Week 52
Number of Female Participants at Stage I-V of Sexual Development Per Tanner Staging of Sexual Development
The Tanner Staging of sexual development is a scale of physical development as children transition into adolescence and then adulthood. The scale defines physical measurements of development based on characteristics, such as the size of the breasts, genitals, testicular volume, and growth of pubic hair. The scale ranges from stage I (pre-adolescent) to stage V (adult development). The results presented are for the number of participants at stage I-V of development.
Time frame: Week 52
Number of Male Participants at Stage I-V of Sexual Development Per Tanner Staging of Sexual Development
The Tanner Staging of sexual development is a scale of physical development as children transition into adolescence and then adulthood. The scale defines physical measurements of development based on characteristics, such as the size of the breasts, genitals, testicular volume, and growth of pubic hair. The scale ranges from stage I (pre-adolescent) to stage V (adult development). The results presented are for the number of participants at stage I-V of development.
Time frame: Week 52
Mean Body Weight of Participants During the Placebo-controlled Phase
The participants' body weight in kilograms (kg) was recorded.
Time frame: Baseline and Week 16
Mean Body Weight of Participants During the Apremilast Exposure Period
The participants' body weight in kilograms (kg) was recorded.
Time frame: Baseline and Week 52
Mean Height of Participants During the Placebo-controlled Phase
The participants' height in centimeters (cm) was recorded.
Time frame: Baseline and Week 16
Mean Height of Participants During the Apremilast Exposure Period
The participants' height in centimeters (cm) was recorded.
Time frame: Baseline and Week 52
Mean Body Mass Index (BMI) of Participants During the Placebo-controlled Phase
The participants' BMI was calculated as body weight (kg)/height (m\^2).
Time frame: Baseline and Week 16
Mean BMI of Participants During the Apremilast Exposure Period
The participants' BMI was calculated as body weight (kg)/height (m\^2).
Time frame: Baseline and Week 52
Number of Participants Who Experienced a Psoriasis Flare During the Placebo-controlled Phase
A psoriasis flare was defined as a sudden intensification of psoriasis (new generalized erythrodermic, inflammatory or pustular psoriasis) requiring medical intervention beyond allowable medications.
Time frame: 16 weeks
Number of Participants Who Experienced a Psoriasis Flare During the Apremilast Exposure Period
A psoriasis flare was defined as a sudden intensification of psoriasis (new generalized erythrodermic, inflammatory or pustular psoriasis) requiring medical intervention beyond allowable medications.
Time frame: 52 weeks
Number of Participants Who Experienced a Psoriasis Rebound
A psoriasis rebound was defined as an adverse event of psoriasis that started after the last dose date for participants who received treatment in the study.
Time frame: 14 weeks post last dose (max mean treatment duration in placebo-controlled phase was 15.3 weeks, and 41.9 weeks in the apremilast-exposure period)
Participants were enrolled into this study at sites in Belgium, Canada, Czech Republic, France, Israel, Italy, Russia, Spain, and the United States.
| Milestone | Placebo | Apremilast | Placebo/Apremilast | Apremilast/Apremilast |
|---|---|---|---|---|
| Started | 82 | 163 | 0 | 0 |
| Took at least 1 dose of investigational product (ip) | 80 | 163 | 0 | 0 |
| Completed | 72 | 149 | 0 | 0 |
| Not completed | 10 | 14 | 0 | 0 |
| Withdrew: Adverse event | 1 | 5 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 0 | 0 | 0 |
| Withdrew: Miscellaneous | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 3 | 5 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 3 | 0 | 0 |
| Milestone | Placebo | Apremilast | Placebo/Apremilast | Apremilast/Apremilast |
|---|---|---|---|---|
| Started | 0 | 0 | 72 | 149 |
| Received apremilast 20mg bid in either placebo-controlled or apremilast extension phases (week 0-52) | 0 | 0 | 36 | 80 |
| Received apremilast 30mg bid in either placebo-controlled or apremilast extension phases (week 0-52) | 0 | 0 | 36 | 83 |
| Took at least 1 dose of ip | 0 | 0 | 72 | 149 |
| Completed | 0 | 0 | 61 | 125 |
| Not completed | 0 | 0 | 11 | 24 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 3 |
| Withdrew: Lack of efficacy | 0 | 0 | 3 | 8 |
| Withdrew: Adverse event | 0 | 0 | 3 | 1 |
| Withdrew: Miscellaneous | 0 | 0 | 2 | 1 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 1 | 8 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 1 | 1 |
| Milestone | Placebo | Apremilast | Placebo/Apremilast | Apremilast/Apremilast |
|---|---|---|---|---|
| Started | 1 | 4 | 14 | 26 |
| Completed | 1 | 3 | 11 | 23 |
| Not completed | 0 | 1 | 3 | 3 |
| Withdrew: Miscellaneous | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 1 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 |
The sPGA is the assessment by the Investigator of the overall disease severity of plaque psoriasis at the time of evaluation. The sPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation. The results presented are for the percentage of participants with a sPGA response. An sPGA response was defined as a score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline at Week 16.
| percentage of participants | Placebo | Apremilast |
|---|---|---|
| Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 | 11.5 | 33.1 |
The Psoriasis Area Severity Index (PASI) is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. The results presented are for the percentage of participants with PASI-75. PASI-75 was defined as at least a 75% reduction in PASI score from baseline.
| percentage of participants | Placebo | Apremilast |
|---|---|---|
| Percentage of Participants Who Achieved At Least 75% Reduction in Psoriasis Area Severity Index (PASI-75) From Baseline at Week 16 | 16.1 | 45.4 |
The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. The results presented are for the percentage of participants with PASI-50. PASI-50 was defined as at least a 50% reduction in PASI score from baseline.
| percentage of participants | Placebo | Apremilast |
|---|---|---|
| Percentage of Participants Who Achieved At Least 50% Reduction in Psoriasis Area Severity Index (PASI-50) From Baseline at Week 16 | 32.1 | 70.5 |
The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Positive percentage change from baseline scores indicate a worsening of disease severity, and negative percentage change from baseline scores indicate an improvement in disease severity.
| percentage change | Placebo | Apremilast |
|---|---|---|
| Percentage Change From Baseline in Total PASI Score at Week 16 | -37.49 ± 3.866 | -64.52 ± 2.543 |
BSA is a measurement of involved skin of the whole body affected by psoriasis, which ranges from 0% to 100%. Positive percentage change from baseline indicates that a greater BSA was affected by psoriasis. A negative percentage change from baseline indicates that a lesser BSA was affected by psoriasis.
| percentage change in affected BSA | Placebo | Apremilast |
|---|---|---|
| Percentage Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis at Week 16 | -20.56 ± 5.441 | -55.44 ± 3.428 |
The CDLQI is designed to measure the impact of skin disease on children's quality of life. The CDLQI measures how much the participant's psoriasis has affected them over the last week, and includes 10 questions with possible answers ranging from not at all (score of 0) to very much (score of 3). The CDLQI total score ranged from 0 (no effect on the participant's life) to 30 (extremely large effect on the participant's life). The results presented are for the percentage of participants who achieved a total CDLQI score of 0 or 1 at Week 16.
| percentage of participants | Placebo | Apremilast |
|---|---|---|
| Percentage of Participants Who Achieved a Children's Dermatology Life Quality Index (CDLQI) Score of 0 or 1 at Week 16 | 31.3 | 35.4 |
The CDLQI is designed to measure the impact of skin disease on children's quality of life. The CDLQI measures how much the participant's psoriasis has affected them over the last week, and includes 10 questions with possible answers ranging from not at all (score of 0) to very much (score of 3). The CDLQI total score ranged from 0 (no effect on the participant's life) to 30 (extremely large effect on the participant's life). A positive change from baseline score indicates that a participant's quality of life has worsened. A negative change from baseline score indicates that a participant's quality of life has improved.
| scores on a scale | Placebo | Apremilast |
|---|---|---|
| Change From Baseline in CDLQI Score at Week 16 | -2.7 ± 0.56 | -5.3 ± 0.44 |
An adverse event (AE) was defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of the study. A TEAE is any AE that occurred after first dose of the investigational product.
| Participants | Placebo | Apremilast 20mg | Apremilast 30 mg |
|---|---|---|---|
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) During the Placebo-controlled Phase | 33 | 58 | 48 |
An AE was defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of the study. A TEAE is any AE that occurred after first dose of the investigational product.
| Participants | Apremilast Exposure Period: Apremilast 20 mg BID | Apremilast Exposure Period: Apremilast 30 mg BID |
|---|---|---|
| Number of Participants Who Experienced a TEAE During the Apremilast Exposure Period | 88 | 80 |
A TESAE is any AE occurring at any dose after first dose that results in death, is life-threatening (ie, in the opinion of the Investigator, the participant is at immediate risk of death from the AE), requires inpatient hospitalization or prolongation of existing hospitalization (hospitalization is defined as an inpatient admission, regardless of length of stay), results in persistent or significant disability/incapacity (a substantial disruption of the participant's ability to conduct normal life functions), is a congenital anomaly/birth defect, or constitutes an important medical event.
| Participants | Placebo | Apremilast 20mg | Apremilast 30 mg |
|---|---|---|---|
| Number of Participants Who Experienced a Treatment-emergent Serious Adverse Event (TESAE) During the Placebo-controlled Phase | 1 | 2 | 0 |
A TESAE is any AE occurring at any dose after first dose that results in death, is life-threatening (ie, in the opinion of the Investigator, the participant is at immediate risk of death from the AE), requires inpatient hospitalization or prolongation of existing hospitalization (hospitalization is defined as an inpatient admission, regardless of length of stay), results in persistent or significant disability/incapacity (a substantial disruption of the participant's ability to conduct normal life functions), is a congenital anomaly/birth defect, or constitutes an important medical event.
| Participants | Apremilast Exposure Period: Apremilast 20 mg BID | Apremilast Exposure Period: Apremilast 30 mg BID |
|---|---|---|
| Number of Participants Who Experienced a TESAE During the Apremilast Exposure Period | 2 | 1 |
A TREAE is any AE that is determined by the Investigator to have a possibly causal relationship to the investigational product.
| Participants | Placebo | Apremilast 20mg | Apremilast 30 mg |
|---|---|---|---|
| Number of Participants Who Experienced a Treatment-related Adverse Event (TRAE) During the Placebo-controlled Phase | 12 | 36 | 32 |
A TREAE is any AE that is determined by the Investigator to have a possibly causal relationship to the investigational product.
| Participants | Apremilast Exposure Period: Apremilast 20 mg BID | Apremilast Exposure Period: Apremilast 30 mg BID |
|---|---|---|
| Number of Participants Who Experienced a TRAE During the Apremilast Exposure Period | 45 | 47 |
Diarrhea was defined as having 3 or more liquid or watery stools in a day. Participants and their parent/guardian were supplied with diaries (either paper or electronic) that were filled out daily to record and describe any diarrhea and associated symptoms.
| Participants | Placebo | Apremilast |
|---|---|---|
| Day 1 to 28 | 25 | 67 |
| Day 29 to 56 | 20 | 51 |
| Day 57 to 84 | 14 | 41 |
| Day 85 to 112 | 10 | 29 |
| Day >/= 113 | 2 | 9 |
Diarrhea was defined as having 3 or more liquid or watery stools in a day. Participants and their parent/guardian were supplied with diaries (either paper or electronic) that were filled out daily to record and describe any diarrhea and associated symptoms.
| Participants | Apremilast Exposure Period: Apremilast 20 mg BID | Apremilast Exposure Period: Apremilast 30 mg BID |
|---|---|---|
| Day 1 to 28 | 36 | 47 |
| Day 29 to 56 | 30 | 36 |
| Day 57 to 84 | 22 | 32 |
| Day 85 to 112 | 17 | 19 |
| Day 113 to 140 | 21 | 17 |
| Day 141 to 168 | 16 | 21 |
| Day 169 to 196 | 19 | 17 |
| Day 197 to 224 | 19 | 12 |
| Day 225 to 252 | 20 | 12 |
| Day 253 to 280 | 18 | 16 |
| Day 281 to 308 | 13 | 9 |
| Day 309 to 336 | 12 | 5 |
| Day 337 to 364 | 7 | 5 |
| Day >= 365 | 1 | 1 |
Diarrhea symptoms were nausea, vomiting, abdominal cramps, abdominal pain, fever, bloating, and other symptoms. Participants and their parent/guardian were supplied with diaries (either paper or electronic) that were filled out daily to record and describe any diarrhea and associated symptoms.
| Participants | Placebo | Apremilast |
|---|---|---|
| Day 1 to 28 — Nausea | 3 | 32 |
| Day 1 to 28 — Vomiting | 2 | 13 |
| Day 1 to 28 — Abdominal cramps | 3 | 16 |
| Day 1 to 28 — Abdominal pain | 9 | 28 |
| Day 1 to 28 — Fever | 1 | 5 |
| Day 1 to 28 — Bloating | 1 | 8 |
| Day 1 to 28 — Other symptoms | 5 | 21 |
| Day 1 to 28 — No symptoms | 53 | 33 |
| Day 29 to 56 — Nausea | 2 | 22 |
| Day 29 to 56 — Vomiting | 2 | 6 |
| Day 29 to 56 — Abdominal cramps | 3 | 7 |
| Day 29 to 56 — Abdominal pain | 9 | 17 |
| Day 29 to 56 — Fever | 0 | 1 |
| Day 29 to 56 — Bloating | 4 | 12 |
| Day 29 to 56 — Other symptoms | 4 | 17 |
| Day 29 to 56 — No symptoms | 56 | 81 |
| Day 57 to 84 — Nausea | 1 | 12 |
| Day 57 to 84 — Vomiting | 0 | 7 |
| Day 57 to 84 — Abdominal cramps | 1 | 9 |
| Day 57 to 84 — Abdominal pain | 5 | 13 |
| Day 57 to 84 — Fever | 0 | 2 |
| Day 57 to 84 — Bloating | 2 | 6 |
| Day 57 to 84 — Other symptoms | 6 | 11 |
| Day 57 to 84 — No symptoms | 65 | 103 |
| Day 85 to 112 — Nausea | 2 | 8 |
| Day 85 to 112 — Vomiting | 1 | 3 |
| Day 85 to 112 — Abdominal cramps | 1 | 5 |
| Day 85 to 112 — Abdominal pain | 2 | 7 |
| Day 85 to 112 — Fever | 0 | 2 |
| Day 85 to 112 — Bloating | 3 | 5 |
| Day 85 to 112 — Other symptoms | 5 | 8 |
| Day 85 to 112 — No symptoms | 66 | 125 |
| Day >/= 113 — Nausea | 0 | 2 |
| Day >/= 113 — Vomiting | 0 | 1 |
| Day >/= 113 — Abdominal cramps | 0 | 1 |
| Day >/= 113 — Abdominal pain | 0 | 2 |
| Day >/= 113 — Fever | 0 | 0 |
| Day >/= 113 — Bloating | 1 | 1 |
| Day >/= 113 — Other symptoms | 0 | 2 |
| Day >/= 113 — No symptoms | 79 | 154 |
Diarrhea symptoms were nausea, vomiting, abdominal cramps, abdominal pain, fever, bloating, and other symptoms. Participants and their parent/guardian were supplied with diaries (either paper or electronic) that were filled out daily to record and describe any diarrhea and associated symptoms.
| Participants | Apremilast Exposure Period: Apremilast 20 mg BID | Apremilast Exposure Period: Apremilast 30 mg BID |
|---|---|---|
| Day 1 to 28 — Nausea | 17 | 21 |
| Day 1 to 28 — Vomiting | 10 | 4 |
| Day 1 to 28 — Abdominal cramps | 7 | 9 |
| Day 1 to 28 — Abdominal pain | 21 | 14 |
| Day 1 to 28 — Fever | 2 | 3 |
| Day 1 to 28 — Bloating | 3 | 7 |
| Day 1 to 28 — Other symptoms | 11 | 13 |
| Day 1 to 28 — No symptoms | 38 | 43 |
| Day 29 to 56 — Nausea | 14 | 10 |
| Day 29 to 56 — Vomiting | 4 | 3 |
| Day 29 to 56 — Abdominal cramps | 4 | 4 |
| Day 29 to 56 — Abdominal pain | 13 | 8 |
| Day 29 to 56 — Fever | 1 | 0 |
| Day 29 to 56 — Bloating | 4 | 9 |
| Day 29 to 56 — Other symptoms | 9 | 9 |
| Day 29 to 56 — No symptoms | 59 | 70 |
| Day 57 to 84 — Nausea | 6 | 8 |
| Day 57 to 84 — Vomiting | 6 | 4 |
| Day 57 to 84 — Abdominal cramps | 8 | 3 |
| Day 57 to 84 — Abdominal pain | 10 | 6 |
| Day 57 to 84 — Fever | 1 | 1 |
| Day 57 to 84 — Bloating | 1 | 6 |
| Day 57 to 84 — Other symptoms | 10 | 6 |
| Day 57 to 84 — No symptoms | 59 | 76 |
| Day 85 to 112 — Nausea | 3 | 5 |
| Day 85 to 112 — Vomiting | 3 | 0 |
| Day 85 to 112 — Abdominal cramps | 4 | 2 |
| Day 85 to 112 — Abdominal pain | 6 | 3 |
| Day 85 to 112 — Fever | 1 | 2 |
| Day 85 to 112 — Bloating | 2 | 4 |
| Day 85 to 112 — Other symptoms | 5 | 4 |
| Day 85 to 112 — No symptoms | 76 | 86 |
| Day 113 to 140 — Nausea | 6 | 2 |
| Day 113 to 140 — Vomiting | 5 | 1 |
| Day 113 to 140 — Abdominal cramps | 4 | 0 |
| Day 113 to 140 — Abdominal pain | 7 | 3 |
| Day 113 to 140 — Fever | 1 | 0 |
| Day 113 to 140 — Bloating | 3 | 2 |
| Day 113 to 140 — Other symptoms | 5 | 3 |
| Day 113 to 140 — No symptoms | 68 | 95 |
| Day 141 to 168 — Nausea | 5 | 2 |
| Day 141 to 168 — Vomiting | 3 | 1 |
| Day 141 to 168 — Abdominal cramps | 2 | 1 |
| Day 141 to 168 — Abdominal pain | 4 | 2 |
| Day 141 to 168 — Fever | 0 | 0 |
| Day 141 to 168 — Bloating | 2 | 2 |
| Day 141 to 168 — Other symptoms | 3 | 1 |
| Day 141 to 168 — No symptoms | 79 | 95 |
| Day 169 to 196 — Nausea | 3 | 4 |
| Day 169 to 196 — Vomiting | 2 | 1 |
| Day 169 to 196 — Abdominal cramps | 1 | 2 |
| Day 169 to 196 — Abdominal pain | 7 | 5 |
| Day 169 to 196 — Fever | 0 | 2 |
| Day 169 to 196 — Bloating | 0 | 1 |
| Day 169 to 196 — Other symptoms | 7 | 0 |
| Day 169 to 196 — No symptoms | 76 | 87 |
| Day 197 to 224 — Nausea | 5 | 2 |
| Day 197 to 224 — Vomiting | 5 | 0 |
| Day 197 to 224 — Abdominal cramps | 1 | 0 |
| Day 197 to 224 — Abdominal pain | 3 | 1 |
| Day 197 to 224 — Fever | 2 | 0 |
| Day 197 to 224 — Bloating | 1 | 1 |
| Day 197 to 224 — Other symptoms | 4 | 1 |
| Day 197 to 224 — No symptoms | 72 | 97 |
| Day 225 to 252 — Nausea | 9 | 3 |
| Day 225 to 252 — Vomiting | 3 | 0 |
| Day 225 to 252 — Abdominal cramps | 2 | 1 |
| Day 225 to 252 — Abdominal pain | 7 | 1 |
| Day 225 to 252 — Fever | 0 | 0 |
| Day 225 to 252 — Bloating | 3 | 1 |
| Day 225 to 252 — Other symptoms | 4 | 0 |
| Day 225 to 252 — No symptoms | 64 | 92 |
| Day 253 to 280 — Nausea | 5 | 4 |
| Day 253 to 280 — Vomiting | 1 | 0 |
| Day 253 to 280 — Abdominal cramps | 3 | 1 |
| Day 253 to 280 — Abdominal pain | 6 | 3 |
| Day 253 to 280 — Fever | 1 | 0 |
| Day 253 to 280 — Bloating | 2 | 1 |
| Day 253 to 280 — Other symptoms | 3 | 2 |
| Day 253 to 280 — No symptoms | 55 | 58 |
| Day 281 to 308 — Nausea | 2 | 3 |
| Day 281 to 308 — Vomiting | 1 | 2 |
| Day 281 to 308 — Abdominal cramps | 1 | 2 |
| Day 281 to 308 — Abdominal pain | 4 | 2 |
| Day 281 to 308 — Fever | 0 | 0 |
| Day 281 to 308 — Bloating | 0 | 1 |
| Day 281 to 308 — Other symptoms | 1 | 1 |
| Day 281 to 308 — No symptoms | 52 | 49 |
| Day 309 to 336 — Nausea | 2 | 1 |
| Day 309 to 336 — Vomiting | 2 | 0 |
| Day 309 to 336 — Abdominal cramps | 1 | 0 |
| Day 309 to 336 — Abdominal pain | 4 | 0 |
| Day 309 to 336 — Fever | 1 | 0 |
| Day 309 to 336 — Bloating | 1 | 0 |
| Day 309 to 336 — Other symptoms | 4 | 1 |
| Day 309 to 336 — No symptoms | 47 | 57 |
| Day 337 to 364 — Nausea | 2 | 1 |
| Day 337 to 364 — Vomiting | 1 | 0 |
| Day 337 to 364 — Abdominal cramps | 0 | 0 |
| Day 337 to 364 — Abdominal pain | 2 | 2 |
| Day 337 to 364 — Fever | 0 | 0 |
| Day 337 to 364 — Bloating | 1 | 0 |
| Day 337 to 364 — Other symptoms | 1 | 1 |
| Day 337 to 364 — No symptoms | 52 | 54 |
| Day >= 365 — Nausea | 0 | 0 |
| Day >= 365 — Vomiting | 0 | 0 |
| Day >= 365 — Abdominal cramps | 0 | 1 |
| Day >= 365 — Abdominal pain | 0 | 0 |
| Day >= 365 — Fever | 0 | 0 |
| Day >= 365 — Bloating | 0 | 0 |
| Day >= 365 — Other symptoms | 0 | 0 |
| Day >= 365 — No symptoms | 24 | 21 |
The C-SSRS is a questionnaire that is used to assess suicidal ideation and behavior. The C-SSRS questionnaire measures suicidal ideation, intensity of ideation, and suicidal behaviors. Results presented are for the number of participants who recorded suicidal ideation or behavior on the C-SSRS.
| Participants | Placebo | Apremilast |
|---|---|---|
| Number of Participants With Suicidal Ideation or Behavior Per the Columbia-Suicide Severity Rating Scale (C-SSRS) During the Placebo-controlled Phase | 0 | 0 |
The C-SSRS is a questionnaire that is used to assess suicidal ideation and behavior. The C-SSRS questionnaire measures suicidal ideation, intensity of ideation, and suicidal behaviors. Results presented are for the number of participants who recorded suicidal ideation or behavior on the C-SSRS.
| Participants | Apremilast-extension Phase: Apremilast 20 mg BID | Apremilast-extension Phase: Apremilast 30 mg BID |
|---|---|---|
| Number of Participants With Suicidal Ideation or Behavior Per the C-SSRS During the Apremilast-extension Phase | 0 | 0 |
The Tanner Staging of sexual development is a scale of physical development as children transition into adolescence and then adulthood. The scale defines physical measurements of development based on characteristics, such as the size of the breasts, genitals, testicular volume, and growth of pubic hair. The scale ranges from stage I (pre-adolescent) to stage V (adult development). The results presented are for the number of participants at stage I-V of development.
| Participants | Placebo | Apremilast |
|---|---|---|
| Breast Growth — Stage 1 | 8 | 17 |
| Breast Growth — Stage 2 | 3 | 9 |
| Breast Growth — Stage 3 | 3 | 9 |
| Breast Growth — Stage 4 | 6 | 20 |
| Breast Growth — Stage 5 | 12 | 27 |
| Breast Growth — Missing | 5 | 7 |
| Pubic Hair Growth — Stage 1 | 8 | 18 |
| Pubic Hair Growth — Stage 2 | 3 | 9 |
| Pubic Hair Growth — Stage 3 | 3 | 9 |
| Pubic Hair Growth — Stage 4 | 6 | 18 |
| Pubic Hair Growth — Stage 5 | 12 | 28 |
| Pubic Hair Growth — Missing | 5 | 7 |
| Other Changes — Stage 1 | 8 | 18 |
| Other Changes — Stage 2 | 3 | 9 |
| Other Changes — Stage 3 | 3 | 12 |
| Other Changes — Stage 4 | 4 | 16 |
| Other Changes — Stage 5 | 12 | 26 |
| Other Changes — Missing | 7 | 8 |
The Tanner Staging of sexual development is a scale of physical development as children transition into adolescence and then adulthood. The scale defines physical measurements of development based on characteristics, such as the size of the breasts, genitals, testicular volume, and growth of pubic hair. The scale ranges from stage I (pre-adolescent) to stage V (adult development). The results presented are for the number of participants at stage I-V of development.
| Participants | Placebo | Apremilast |
|---|---|---|
| Testes Growth — Stage 1 | 11 | 15 |
| Testes Growth — Stage 2 | 5 | 5 |
| Testes Growth — Stage 3 | 4 | 10 |
| Testes Growth — Stage 4 | 5 | 12 |
| Testes Growth — Stage 5 | 14 | 27 |
| Testes Growth — Missing | 4 | 5 |
| Penis Growth — Stage 1 | 11 | 15 |
| Penis Growth — Stage 2 | 5 | 5 |
| Penis Growth — Stage 3 | 4 | 11 |
| Penis Growth — Stage 4 | 5 | 10 |
| Penis Growth — Stage 5 | 14 | 28 |
| Penis Growth — Missing | 4 | 5 |
| Pubic Hair Growth — Stage 1 | 10 | 15 |
| Pubic Hair Growth — Stage 2 | 5 | 6 |
| Pubic Hair Growth — Stage 3 | 5 | 8 |
| Pubic Hair Growth — Stage 4 | 6 | 14 |
| Pubic Hair Growth — Stage 5 | 13 | 26 |
| Pubic Hair Growth — Missing | 4 | 5 |
| Other Changes — Stage 1 | 9 | 15 |
| Other Changes — Stage 2 | 5 | 5 |
| Other Changes — Stage 3 | 4 | 8 |
| Other Changes — Stage 4 | 4 | 11 |
| Other Changes — Stage 5 | 14 | 26 |
| Other Changes — Missing | 7 | 9 |
The participants' body weight in kilograms (kg) was recorded.
| kg | Placebo | Apremilast |
|---|---|---|
| Baseline | 52.36 ± 22.177 | 52.04 ± 21.123 |
| Week 16 | 54.18 ± 22.581 | 51.95 ± 20.945 |
The participants' body weight in kilograms (kg) was recorded.
| kg | Apremilast Exposure Period: Apremilast 20 mg BID | Apremilast Exposure Period: Apremilast 30 mg BID |
|---|---|---|
| Baseline | 36.81 ± 8.954 | 67.94 ± 19.053 |
| Week 52 | 39.04 ± 9.823 | 67.79 ± 18.889 |
The participants' height in centimeters (cm) was recorded.
| cm | Placebo | Apremilast |
|---|---|---|
| Baseline | 153.29 ± 18.435 | 153.33 ± 18.069 |
| Week 16 | 154.54 ± 17.839 | 154.40 ± 17.683 |
The participants' height in centimeters (cm) was recorded.
| cm | Apremilast Exposure Period: Apremilast 20 mg BID | Apremilast Exposure Period: Apremilast 30 mg BID |
|---|---|---|
| Baseline | 140.86 ± 14.159 | 166.13 ± 11.416 |
| Week 52 | 144.90 ± 13.944 | 167.84 ± 10.814 |
The participants' BMI was calculated as body weight (kg)/height (m\^2).
| kg/m^2 | Placebo | Apremilast |
|---|---|---|
| Baseline | 21.41 ± 5.652 | 21.33 ± 5.197 |
| Week 16 | 21.87 ± 5.883 | 20.98 ± 5.067 |
The participants' BMI was calculated as body weight (kg)/height (m\^2).
| kg/m^2 | Apremilast Exposure Period: Apremilast 20 mg BID | Apremilast Exposure Period: Apremilast 30 mg BID |
|---|---|---|
| Baseline | 18.32 ± 2.641 | 24.52 ± 5.655 |
| Week 52 | 18.30 ± 2.480 | 23.95 ± 5.539 |
A psoriasis flare was defined as a sudden intensification of psoriasis (new generalized erythrodermic, inflammatory or pustular psoriasis) requiring medical intervention beyond allowable medications.
| Participants | Placebo | Apremilast |
|---|---|---|
| Number of Participants Who Experienced a Psoriasis Flare During the Placebo-controlled Phase | 3 | 2 |
A psoriasis flare was defined as a sudden intensification of psoriasis (new generalized erythrodermic, inflammatory or pustular psoriasis) requiring medical intervention beyond allowable medications.
| Participants | Apremilast Exposure Period: Apremilast 20 mg BID | Apremilast Exposure Period: Apremilast 30 mg BID |
|---|---|---|
| Number of Participants Who Experienced a Psoriasis Flare During the Apremilast Exposure Period | 7 | 11 |
A psoriasis rebound was defined as an adverse event of psoriasis that started after the last dose date for participants who received treatment in the study.
| Participants | Placebo | Apremilast 20 mg BID | Apremilast 30 mg BID |
|---|---|---|---|
| Number of Participants Who Experienced a Psoriasis Rebound | 0 | 0 | 4 |
Collected over Up to a maximum of 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo-Controlled Phase: Placebo BID | 0/82 (0%) | 1/80 (1.3%) | 26/80 (32.5%) |
| Placebo-Controlled Phase: Apremilast 20 mg BID | 0/80 (0%) | 2/80 (2.5%) | 50/80 (62.5%) |
| Placebo-Controlled Phase: Apremilast 30 mg BID | 0/83 (0%) | 0/83 (0%) | 41/83 (49.4%) |
| Placebo-Controlled Phase: Apremilast BID | 0/163 (0%) | 2/163 (1.2%) | 91/163 (55.8%) |
| Apremilast Extension Phase: Apremilast 20 mg BID | 0/110 (0%) | 0/110 (0%) | 52/110 (47.3%) |
| Apremilast Extension Phase: Apremilast 30 mg BID | 0/111 (0%) | 2/111 (1.8%) | 38/111 (34.2%) |
| Apremilast Extension Phase: Apremilast BID | 0/221 (0%) | 2/221 (0.9%) | 90/221 (40.7%) |
| Event | Placebo-Controlled Phase: Placebo BID | Placebo-Controlled Phase: Apremilast 20 mg BID | Placebo-Controlled Phase: Apremilast 30 mg BID | Placebo-Controlled Phase: Apremilast BID | Apremilast Extension Phase: Apremilast 20 mg BID | Apremilast Extension Phase: Apremilast 30 mg BID | Apremilast Extension Phase: Apremilast BID |
|---|---|---|---|---|---|---|---|
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/80 | 1/80 | 0/83 | 1/163 | 0/110 | 0/111 | 0/221 |
| Sinus tachycardiaCardiac disorders | 0/80 | 1/80 | 0/83 | 1/163 | 0/110 | 0/111 | 0/221 |
| Wandering pacemakerCardiac disorders | 0/80 | 1/80 | 0/83 | 1/163 | 0/110 | 0/111 | 0/221 |
| Autonomic nervous system imbalanceNervous system disorders | 0/80 | 1/80 | 0/83 | 1/163 | 0/110 | 0/111 | 0/221 |
| Testicular appendage torsionReproductive system and breast disorders | 1/80 | 0/80 | 0/83 | 0/163 | 0/110 | 0/111 | 0/221 |
| PsoriasisSkin and subcutaneous tissue disorders | 0/80 | 1/80 | 0/83 | 1/163 | 0/110 | 0/111 | 0/221 |
| AppendicitisInfections and infestations | 0/80 | 0/80 | 0/83 | 0/163 | 0/110 | 1/111 | 1/221 |
| Status migrainosusNervous system disorders | 0/80 | 0/80 | 0/83 | 0/163 | 0/110 | 1/111 | 1/221 |
| Event | Placebo-Controlled Phase: Placebo BID | Placebo-Controlled Phase: Apremilast 20 mg BID | Placebo-Controlled Phase: Apremilast 30 mg BID | Placebo-Controlled Phase: Apremilast BID | Apremilast Extension Phase: Apremilast 20 mg BID | Apremilast Extension Phase: Apremilast 30 mg BID | Apremilast Extension Phase: Apremilast BID |
|---|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 8/80 | 23/80 | 9/83 | 32/163 | 14/110 | 5/111 | 19/221 |
| DiarrhoeaGastrointestinal disorders | 8/80 | 15/80 | 17/83 | 32/163 | 20/110 | 13/111 | 33/221 |
| NauseaGastrointestinal disorders | 2/80 | 15/80 | 17/83 | 32/163 | 18/110 | 10/111 | 28/221 |
| VomitingGastrointestinal disorders | 2/80 | 16/80 | 13/83 | 29/163 | 15/110 | 7/111 | 22/221 |
| HeadacheNervous system disorders | 4/80 | 12/80 | 5/83 | 17/163 | 7/110 | 5/111 | 12/221 |
| PsoriasisSkin and subcutaneous tissue disorders | 3/80 | 0/80 | 2/83 | 2/163 | 5/110 | 11/111 | 16/221 |
| PyrexiaGeneral disorders | 1/80 | 7/80 | 3/83 | 10/163 | 4/110 | 1/111 | 5/221 |
| DyspepsiaGastrointestinal disorders | 0/80 | 3/80 | 7/83 | 10/163 | 2/110 | 2/111 | 4/221 |
| NasopharyngitisInfections and infestations | 3/80 | 5/80 | 5/83 | 10/163 | 8/110 | 3/111 | 11/221 |
| Abdominal pain upperGastrointestinal disorders | 4/80 | 5/80 | 4/83 | 9/163 | 5/110 | 0/111 | 5/221 |
Measured in the intent-to-treat (ITT) population, which included all participants who were randomized.
| Age, Continuous(years) | Placebo | Apremilast | Total |
|---|---|---|---|
| Mean | 12.2 ± 3.25 | 12.3 ± 3.32 | 12.2 ± 3.29 |
| Sex: Female, Male(Participants) | Placebo | Apremilast | Total |
|---|---|---|---|
| Female | 39 | 89 | 128 |
| Male | 43 | 74 | 117 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Apremilast | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 24 | 32 |
| Not Hispanic or Latino | 71 | 129 | 200 |
| Unknown or Not Reported | 3 | 10 | 13 |
| Race (NIH/OMB)(Participants) | Placebo | Apremilast | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 |
| Asian | 3 | 6 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 5 | 8 |
| White | 73 | 140 | 213 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 10 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Dec 2018 to primary completion in Apr 2022, 40 months.
Results were first posted in Dec 2023, 1 year 7 months after primary completion. A results delay was requested in Oct 2022.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 40 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast